Dengue is a major global public health problem requiring a safe and efficacious vaccine as
the foundation of a comprehensive countermeasure strategy. Despite decades of attempts …

Opinion statement Dengue viruses (DENV) continue to circulate worldwide, resulting in a
significant burden on human health. There are four antigenically distinct serotypes of DENV …

Abstract Background Butantan–Dengue Vaccine (Butantan-DV) is an investigational, single-
dose, live, attenuated, tetravalent vaccine against dengue disease, but data on its overall …

Dengue is one of the most prevalent mosquito-borne diseases in the world, affecting an
estimated 390 million people each year, according to models. For the last two decades …

The quest for an effective dengue vaccine has culminated in two approved vaccines and
another that has completed phase 3 clinical trials. However, shortcomings exist in each …

The timelines for developing vaccines against infectious diseases are lengthy, and often
vaccines that reach the stage of large phase 3 field trials fail to provide the desired level of …

Dengue is the most common arboviral disease caused by one of four distinct but closely
related dengue viruses (DENV) and places significant economic and public health burdens …

Introduction: Dengue virus is a global health threat, with approximately 390 million dengue
infections annually. Efficient vaccines for dengue prevention are currently lacking. This …

Commemorating the 2021 ASEAN Dengue Day and advocacy for World Dengue Day, the
International Society for Neglected Tropical Diseases (ISNTD) and Asian Dengue Voice and …

Infection with dengue virus (DENV) leads to symptoms variable from dengue fever to severe
dengue, which has posed a huge socioeconomic and disease burden to the world …